Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
PERI
Sam Chun Dang Pharm
★★
Sam Chun Dang Pharm 82nd Business Report Analysis: Aflibercept Biosimilar Commercialization and Consolidated Operating Profit Turnaround Signal Improved Shareholder Value
3h ago
EXCH
Sam Chun Dang Pharm
★
Sam Chun Dang Pharm Receives EMA Phase 1 Approval for Oral Insulin SCD0503; Pipeline Advances but Uncertainty Remains
05/29/2026, 07:49 AM
EXCH
Sam Chun Dang Pharm
★
Convocation of EGM and Appointment of Outside Director
05/16/2026, 07:51 PM
OTHR
Sam Chun Dang Pharm
★
Outside Director Change Report Filed (No Details Provided)
05/16/2026, 07:51 PM
EXCH
Sam Chun Dang Pharm
★
Record Date Set for 2026 Extraordinary General Meeting
05/16/2026, 07:51 PM
PERI
Sam Chun Dang Pharm
★★★★
Sam Chun Dang Pharm Q1 2026 Strong Results, Expanded Biosimilar and Oral Semaglutide Contracts
05/15/2026, 04:10 PM